Publications in Peer-Reviewed Journals


Brett J, Elshaug AG, Bhatia RS, Chalmers K et al. (2017). “A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.” Implementation Science. 12:58


Doos L, Packer C, Ward D, Simpson S, Stevens A. (2016). “Past speculations of the future: a review of the methods used for forecasting emerging health technologies.” BMJ Open. 6

Ermisch, M, Bucsics A, Bonnano, PV, Arickx F et al. (2016). “Payers’ Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.” 7(305).

Nascimento A, Vidal AT, Almeida RT. (2016). “”Mapping stakeholders’ preferences in prioritization criteria for horizon scanning in healthcaremtechnologies.”” Cad. Saúde Pública, Rio de Janeiro, 32(7):e00177614

Parkinson B, Sermet C, Clement F, Crausaz S et al. (2016). Stratgies de dsinvestissement des produits pharmaceutiques: une revue de littrature internationale. Questions d’conomie de la sant n 220 – Juillet/aot 2016:1-8). 


Parkinson B, Semet C, Clement F, Crausaz S et al. (2015). “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.” Pharmacoeconomics. 33(9): 905-924.

Parkinson B, Sermet C, Clement F, Crausaz S et al. (2015). “Value-Based Purchasing and Disinvestment Strategies for Pharmaceuticals: An International Review.” Pharmacoeconomics. 33(9):905-924


Godman B, Malmstrom RE, Diogene E, Jayathissa S et al. (2014). “Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.” Front. Pharmacol 5

Godman B, Wettermark M, van Woerkom M, Fraeyman J et al. (2014). “Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.” Front Pharmacol 5: 106.

Moon JC, Godman B, Petzold M, Alvarez-Madrazo S et al. (2014). “Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications.” Frontiers in Pharmacology. 5 (Article 219):1-10


Baker DW, Qaseem A, Reynolds PP, Gardner LA et al. (2013). “Design and use of performance measures to decrease low-value services and achieve cost-conscious care.” Ann Intern Med 158(1): 55-59.

Watt AM, Willis CD, Hodgetts K, Elshaug AG, Hiller JE. (2013). “Engaging clinicians in evidence-based disinvestment: role and perceptions of evidence.” Int J Technol Assess Health Care 28(3): 211-219.

Carter D, Watt AM, Braunack-Mayer A, Elshaug A et al. (2013). “Should There Be a Female Age Limit on Public Funding for Assisted Reproductive Technology? Differing Conceptions of Justice in Resource Allocation.” Journal of Bioethical Inquiry, 10 (1), 79-91

Chamberlain CA, Martin RM, Busby J, Gilbert R et al. (2013). “Trends in procedures for infertility and caesarean sections: was NICE disinvestment guidance implemented?” NICE recommendation reminders. 6;13(1):112.

Garca-Armesto S, Campillo-Artero C, Bernal-Delgado E. (2013). “Disinvestment in the age of cost-cutting sound and fury. Tools for the Spanish National Health System.” Health Policy 110(2-3): 180-185.

Garner S, Docherty M, Somner J, Sharma T et al. (2013). “Reducing  ineffective practice: challenges in identifying low-value health care using Cochrane systematic reviews.” J Health Serv Res Policy. 18(1):6-12.

Godman B, Finlayson, AE, Cheema PK, Zebedin-Brandl E et al. (2013). “Personalizing health care: feasibility and future implications.” BMC Med 11: 179.

Kiran T, Kopp A, Moineddin R, Victor JC et al. (2013). “Unintended consequences of delisting routine eye exams on retinopathy screening for people with diabetes in Ontario, Canada.” CMAJ. 185(3):E167-73

Scott, I. A. and Elshaug A. G. (2013). “Foregoing low-value care: how much evidence is needed to change beliefs?” Intern Med J 43(2): 107-109.


Baumgartel C, Godman, B, Malmstrom RE, Andersen M et al. (2012). “What lessons can be learned from the launch of generic clopidogrel?” Generics and Biosimilars Initiative Journal. 1(2):10-20

Brody, H. (2012). “From an ethics of rationing to an ethics of waste avoidance.” N Engl J Med 366(21): 1949-1951.

Elshaug AG, Watt AM, Mundy L, Willis CD. (2012). “Over 150 potentially low-value health care practices: an Australian study.” Med J Aust. 197(10):556-60

Cassel CK and Guest JA. (2012). “Choosing wisely: Helping physicians and patients make smart decisions about their care.” JAMA 307(17): 1801-1802.

Godman B, Malmstrom R, Bennie M, Sakshaug S et al. (2012). “Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?” Reviews in Health Care 3(1).

Henshall C, Schuller T, Mardhani-Bayne L. (2012). “Using health technology assessment to support optimal use of technologies in current practice: the challenge of “disinvestment”.” Int J Technol Assess Health Care. 28(3):203-10.

Hodgetts K, Elshaug AG, Hiller JE. (2012).”What counts and how to count it: physicians’ constructions of evidence in a disinvestment context.” Hodgetts K, Elshaug AG, Hiller JE. Soc Sci Med. 75(12):2191-9.

Klein R and Maybin J. (2012). “Thinking about Rationing.” London, The King’s Fund.

Leggett L, Noseworthy TW, Zarrabi M, Lorenzetti D et al. (2012). “Health technology reassessment of non-drug technologies: current practices.” Int J Technol Assess Health Care 28(3): 220-227.

Qaseem A, Alguire P, Dallas P, Feinberg et al. (2012). “Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care.” Ann Intern Med 156(2): 147-149.

Robinson S, Dickinson H, Freeman T, Rumbold B, Williams I. (2012). “Structures and processes for priority-setting by health-care funders: a national survey of primary care trusts in England.” Halth Serv Manage Res. 25(3):113-20.

Robinson S, Williams I, Dickinson H, Freeman T et al. (2012). “Priority-setting and rationing in healthcare: evidence from the English experience.” (12):2386-93.

Smith N, Mitton C, Cornelissen E, Gibson J et al. (2012). “Using evaluation theory in priority setting and resource allocation.” J Health Organ Manag. 26(4-5):655-71.

Volpp KG, Loewenstein G, Asch DA. (2012). “Choosing wisely: low-value services, utilization, and patient cost sharing.” JAMA 308(16): 1635-1636.

Watt AM, Hiller JE, Braunack-Mayer AJ, Moss JR et al. (2012). “The ASTUTE Health study protocol: deliberative stakeholder engagements to inform implementation approaches to healthcare disinvestment.” Implement Sci. 22;7:101.

Wilt TJ and Qaseem A. (2012). Implementing high-value, cost-conscious diabetes mellitus care through the use of low-cost medications and less-intensive glycemic control target. Arch Intern Med. 12;172(20):1610-1.

Godman B, Wettermark B, Bishop I, Burkhardt T et al. (2012). “European payer initiatives to reduce prescribing costs through use of generics”. Generics and Biosimilars Initiative Journal. 1(1):22-27


Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E et al. (2011). “The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm.” Basic Clin Pharmacol Toxicol 108(4): 224-233.


Adamski J Godman, B, Ofierska-Sujkowska G, Osińska B et al. (2010). “Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.” BMC Health Services Research. 10:153

Godman B, Shrank W, Wettermark B, Andersen M et al. (2010). “Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?” Pharmaceuticals (Basel) 3(8): 2470-2494. 

Godman B, Shrank W, Andersen M, Berg C et al. (2010). “Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.” Expert Rev Pharmacoecon Outcomes Res 10(6): 707-722.


Norman C, Zarrinkoub R, Hasselstrom J, Godman B et al. (2009). “Potential savings without compromising the quality of care.” Int J Clin Pract. 63(9):1320-6


Grattini S, Bertele V, Godman B, Haycox A et al. (2008). “Enhancing the rational use of new medicines across European health care systems.” Eur J Clin Pharmacol. 64:1137–1138

Other Useful Publications